Investigación local. Conexiones humanas. WCR Miami Lakes (786) 483-7856
Volver a buscar estudiosNCT07829107
ReclutandoNCT07829107Registro de ClinicalTrials.gov

The PIONEER Comparative Effectiveness Study - Project 2

Head Injury Trauma · Traumatic Brain Injury, Mild

LO ESENCIAL

De qué trata este estudio

El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.

Tipo de estudio
De intervención
Fase
No aplica
Rango de edad
18 años - No especificado
Sexo admitido
Todos los sexos
Voluntarios sanos
No aceptados
Participantes
3000 Estimado

Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.

Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.

Acerca de la investigación

This is a pragmatic, open-label, multicenter, stepped-wedge, Type II hybrid effectiveness-implementation study. It is designed to evaluate both the comparative effectiveness and implementation feasibility of a biomarker-plus-clinical guidelines algorithm to reduce low-value brain computed tomography (CT) use in emergency department (ED) patients evaluated for suspected traumatic brain injury (TBI). The biomarkers are Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1), two brain-injury proteins cleared by the FDA to support brain CT imaging decisions after trauma. All six participating EDs will contribute baseline data for the first 6 months under usual care (clinical guidelines only). Beginning in month 7, two sites will transition to implementing the biomarker-guided algorithm. At month 13, two additional sites will implement the biomarker-guided approach, and the final two sites will transition at month 19. By the end of the 24-month rollout period, all sites will have implemented the biomarker-guided pathway.

¿Quién podría participar?

La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.

Inclusion

  • Age ≥18 years at the time of the emergency department visit.
  • Presentation to a participating emergency department following a traumatic injury mechanism (motor vehicle collision, fall from height, assault, head injury/head trauma/head strike, struck by or against an object, facial injury or laceration, or other general trauma). Presentations may also include alcohol intoxication or syncope when associated with a suspected traumatic brain injury.
  • Evidence of potential head or brain injury, defined as (i) the head being struck by an object, (ii) the head striking a hard object or surface, (iii) exposure of the brain to significant acceleration/deceleration forces, or (iv) clinician documentation that the patient was evaluated for suspected traumatic brain injury.
  • Glasgow Coma Scale (GCS) score of 13-15 at presentation.
  • Presentation to the emergency department within 24 hours of injury.

Exclusion Criteria:

  • Planned computed tomography (CT) imaging of the maxillofacial bones, chest, abdomen, or pelvis during the ED encounter AND clinicians do not intend to avoid brain CT imaging even if the biomarker test is negative.
  • Current use of anticoagulant or antiplatelet therapy, including but not limited to: Warfarin, Factor Xa inhibitors (e.g., apixaban \[Eliquis\], rivaroxaban \[Xarelto\]), Clopidogrel, Ticagrelor.
  • Presentation \>24 hours after injury, due to the declining diagnostic sensitivity of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) beyond this time window.
Entiende la evaluación inicial

Tratamiento, grupos y participación

El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.

Asignación
Asignación al azar
Enmascaramiento
Sin enmascaramiento
Clinical Pathway 2: Clinical Guidelines Only

Clinical Guidelines Only (Canadian CT Head Rule)

Diagnostic Test: Clinical guidelines only

Clinical Pathway 1: Guidelines + Biomarkers

Canadian CT Head Rule plus whole blood Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) measurement using the i-STAT.

Diagnostic Test: Clinical pathway 1: Guidelines plus biomarkers

Clinical pathway 1: Guidelines plus biomarkers DIAGNOSTIC_TEST

Patients will be managed using an algorithm that integrates the Canadian CT Head Rule (CCHR) with i-STAT whole-blood GFAP and UCH-L1 testing. Patients who meet CCHR criteria for CT imaging and those whose CT imaging decision-making is not covered by CCHR (e.g., no loss of consciousness or amnesia) will receive i-STAT testing. Sites will be assigned to one of three implementation waves, with two sites transitioning to the Guidelines + Biomarkers phase every six months. Prior to their assigned transition, sites will continue to use guidelines alone. Once a site transitions to the Guidelines + Biomarkers phase, the integrated biomarker-guided algorithm will become the standard-of-care protocol at that site for eligible patients and will remain the standard of care for the remainder of the study.

Clinical guidelines only DIAGNOSTIC_TEST

During the baseline phase, sites will rely solely on established clinical guidelines to guide brain CT utilization in patients with suspected TBI. Specifically, providers will apply the Canadian CT Head Rule, a validated decision instrument that identifies patients at high risk for clinically important brain injury who require CT imaging. All sites will begin in this Guidelines-Only baseline phase and will continue using this approach until their assigned transition to the Guidelines + Biomarkers phase. Sites will transition in three waves, with two sites transitioning every six months.

Prepara tus preguntas

Qué evalúan los investigadores

Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.

Medidas principales

The proportion of eligible emergency department (ED) patients with suspected traumatic brain injury (TBI) who receive brain CT imaging.

Plazo: Initial Emergency Department Visit (approximately 24 hours)

No informado en este registro.

Medidas secundarias

Proportion of eligible ED patients with suspected TBI who receive brain CT imaging and have a clinically significant traumatic lesion.

Plazo: Initial Emergency Department Visit (approximately 24 hours)

No informado en este registro.

Incidence of clinically significant missed traumatic intracranial injury diagnosed within 7 days of the index ED visit

Plazo: Within 7 days of the index/initial ED visit

No informado en este registro.

Incidence of neurosurgical interventions within 7 days of the index ED visit, without a new traumatic event.

Plazo: Within 7 days of the index/initial ED visit

No informado en este registro.

ED length of stay

Plazo: Initial Emergency Department Visit (approximately 24 hours)

This will be measured in minutes.

Initial and sustained provider adherence at 6 and 24 months post-implementation

Plazo: 6 and 24 months post-implementation

No informado en este registro.

Provider acceptability and feedback

Plazo: During implementation phase (months 9-32)

Providers will answer 17 questions regarding the implementation of the biomarker-guided algorithm and acceptability. Information from this will be summarized.

Provider trust in biomarker-guided CT decision making as measured by the proportion of biomarker-negative patients who don't get a CT

Plazo: During implementation phase (months 9-32)

No informado en este registro.

30-day ED revisits and hospitalizations

Plazo: 30 days following Initial Emergency Department Visit

No informado en este registro.

El registro no indica resultados publicados.

Revisa las tablas completas y sus limitaciones en el registro oficial.

Abrir resultados oficiales ↗

Centros de investigación (6)

El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.

6 centros

UCLA-Olive View Medical CenterSylmar, California, United StatesReclutando
Yesenia PerezCONTACTYPerez@dhs.lacounty.gov
Breena Taira, MD, MPHPRINCIPAL_INVESTIGATOR
Ver ubicación en el mapa ↗
Harbor-UCLA Medical CenterTorrance, California, United StatesReclutando
Kabir Yadav, MD, MS, MHSHPRINCIPAL_INVESTIGATOR
Ver ubicación en el mapa ↗
Henry Ford Macomb (HFM)Clinton Township, Michigan, United StatesReclutando
Jo-Ann RammalCONTACTJRammal1@hfhs.org313-404-9110
Joseph Miller, MD, MSPRINCIPAL_INVESTIGATOR
Ver ubicación en el mapa ↗
Henry Ford Hospital (HFH)Detroit, Michigan, United StatesReclutando
Jo-Ann RammalCONTACTJRammal1@hfhs.org313-404-9110
Joseph Miller, MD, MSPRINCIPAL_INVESTIGATOR
Ver ubicación en el mapa ↗
Hillsboro Medical CenterPortland, Oregon, United StatesReclutando
Maja Strusinska-ThayerCONTACTstrusins@ohsu.edu503-418-2713
Bory Kea, MD, MCRPRINCIPAL_INVESTIGATOR
Ver ubicación en el mapa ↗
Oregon Health & Science University (OHSU)Portland, Oregon, United StatesReclutando
Maja Strusinska-ThayerCONTACTstrusins@ohsu.edu503-418-2713
Bory Kea, MD, MCRPRINCIPAL_INVESTIGATOR
Ver ubicación en el mapa ↗

Equipo y fechas

Patrocinador principal
University of Michigan
Inicio del estudio
15 oct 2026 Real
Finalización primaria
2029-01 Estimado
Finalización del estudio
2029-01 Estimado
Primera publicación
18 sept 2026 Real
Última actualización
10 nov 2026 Real

Contactos oficiales del estudio

Devon Newman, MSCONTACTdevonn@med.umich.edu734-652-9679
Título oficial del estudio

Comparing the Effectiveness of a Biomarker-plus-clinical Guidelines Algorithm Versus Clinical Guidelines Only for Safely Decreasing Brain Computed Tomography Utilization During Brain Injury Evaluations: The PIONEER Comparative Effectiveness Study

EL PRÓXIMO PASO, CON APOYO HUMANO

Consulta a Wellness Clinical Research

Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.

No incluyas expedientes médicos, diagnósticos, medicamentos, números de seguro ni otros datos sensibles. Este formulario es para preguntas generales, no para atención urgente.

Enviar una pregunta no te inscribe en un estudio.

Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.

Consultado: 11 nov 2026 · Última actualización del registro: 10 nov 2026